HENGRUI PHARMA - An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section

or completeness of this announcement, and expressly expressly disclaims any liability arising out of or in reliance upon the whole or any part of the contents of this announcement. assumes no responsibility for any losses caused by such content.

Jiangsu Hengrui Pharmaceuticals Co., Ltd. Jiangsu Hengrui Pharmaceutical Co., Ltd.

(a joint stock limited company incorporated in the People's Republic of China) (Stock code: 1276)

Overseas regulatory announcement

This announcement is made in accordance with Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

In accordance with the relevant laws and regulations of the People's Republic of China, Jiangsu Hengrui Pharmaceutical Co., Ltd. (the "Company")

The Shanghai Stock Exchange website (www.sse.com.cn) published the following announcement. They are listed below for reference only.

By order of the board of directors Jiangsu Hengrui Pharmaceutical Co., Ltd. Chairman

Mr. Sun Piaoyang

Shanghai, China March 25, 2026

As at the date of this announcement, members of the Board of Directors include (i) Executive Directors Mr. Sun Piaoyang, Mr. Dai Hongbin, and Mr. Feng Jinu; Mr. Zhang Lianshan, Mr. Jiang Ningjun and Mr. Sun Jieping; (ii) Ms. Guo Congzhao, a non-executive director; and (iii)

Independent non-executive directors are Mr. Dong Jiahong, Mr. Zeng Qingsheng, Mr. Sun Jinyun and Mr. Zhou Ji'en.

Securities code: 600276 Securities abbreviation: Hengrui Medicine Announcement number: Lin 2026-051

Jiangsu Hengrui Pharmaceutical Co., Ltd.

Proposal on Purchasing Liability Insurance for Directors and Senior Management

The board of directors and all directors of the company guarantee that the contents of this announcement do not contain any false records or misleading statements.

or major omissions, and assume legal responsibility for the authenticity, accuracy and completeness of its content.

Jiangsu Hengrui Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") held on March 25, 2026

The 24th meeting of the ninth board of directors reviewed the "Regulations on Purchasing Liability Insurance for Directors and Senior Management Personnel" Bill". In order to improve the company's risk management system and protect the rights and interests of the company's directors and senior managers, according to

According to the "Code of Corporate Governance for Listed Companies" and other relevant provisions, the company intends to provide procurement services for the company and all directors and senior managers.

Buy liability insurance.

The specific plan for purchasing liability insurance for directors and senior managers is as follows:

1.Insured person: Jiangsu Hengrui Pharmaceutical Co., Ltd. 2. Insured party: the company and all directors, senior managers and other directly responsible persons

3. Limit of liability: no more than RMB 200 million

4. Premium expenditure: no more than RMB 2 million per year (specifically based on the final quotation data of the insurance company)

accurate)

5. Insurance period: The specific start and end time is subject to the insurance contract, and the insurance can be renewed every year. In order to improve decision-making efficiency, the company's board of directors intends to request the shareholders' meeting to authorize the company's operation and management within the above authority.

Handle matters related to the purchase of liability insurance for the company and all directors and senior managers at the highest level (including but not limited to confirming

Determine other directly responsible persons; determine the insurance company; determine the insurance amount, insurance premium and other insurance terms;

Select and engage insurance brokerage companies or other intermediaries; sign relevant legal documents and handle insurance-related matters other matters, etc.), as well as handling and renewing or re-insurance on or before the expiration of the liability insurance contract in the future.

Regarding insurance and other related matters, renewal or re-insurance is within the scope of the above-mentioned insurance plan and no separate decision is required.

Announcement is hereby made.

Board of Directors of Jiangsu Hengrui Pharmaceutical Co., Ltd.

March 25, 2026